Form 4: Mineralys CMO Executes Planned Stock Sale

Chief Medical Officer David Malcom Rodman exercised stock options and sold shares of Mineralys Therapeutics under a 10b5-1 plan.

Summary

• Chief Medical Officer David Malcom Rodman exercised options for 14,058 shares of common stock at various strike prices ($1.08, $10.20, and $14.25).
• The reporting person sold a total of 20,406 shares across two dates (April 13 and April 15, 2026).
• Sales were executed at weighted-average prices of $26.5391 and $27.66 per share.
• Transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; the transactions are purely administrative and pre-planned, carrying no signal regarding the company's fundamental health.

Positives

• The transactions were pre-planned under a Rule 10b5-1 trading plan, indicating the sales were not based on non-public information.
• The reporting person maintains a significant remaining beneficial ownership of 69,792 shares.

Negatives

• The filing reflects a reduction in the insider's direct equity stake in the company.

Risks

• Future share price volatility could impact the value of remaining unexercised stock options.
• Reliance on Rule 10b5-1 plans does not eliminate market risk for the reporting person.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this ownership disclosure.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice in the biotechnology sector, often used by executives for liquidity and diversification rather than signaling a lack of confidence in the company's clinical pipeline.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to mitigate legal risks associated with insider trading.
• The volume of shares sold is consistent with typical executive compensation liquidation patterns for mid-cap biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the sales were pre-scheduled and executed through a transparent regulatory mechanism.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Mineralys Therapeutics, MLYS, Insider Trading, Form 4, Stock Options, Biotech